法国生物技术公司Abivax周四否认法国媒体关于阿斯利康正在谈判收购该公司的报道。
此前La Lettre的报道称，阿斯利康自2月初以来一直拥有接触Abivax数据的独家权限，并有直到3月23日的时间来正式提出收购要约。
Abivax发言人表示，他们完全否认这一报道，但没有进一步评论文章中的具体内容。阿斯利康早些时候拒绝置评。
数月来，Abivax多次被传为是收购对象，其股价也因此飙升。
在La Lettre的报道发布后，该公司股价周四一度上涨15%，但在午盘交易中涨幅约为4%。
责任编辑：张俊 SF065
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.